Inhibition of human immunodeficiency virus type-1 by cdk inhibitors.

Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. J Virol (2013) 1.00

The phosphorylation of HIV-1 Gag by atypical protein kinase C facilitates viral infectivity by promoting Vpr incorporation into virions. Retrovirology (2014) 0.92

Cellular kinases incorporated into HIV-1 particles: passive or active passengers? Retrovirology (2011) 0.85

Use of ATP analogs to inhibit HIV-1 transcription. Virology (2012) 0.85

Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS (2015) 0.81

Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication. J Virol (2013) 0.79

Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy. PLoS One (2014) 0.78

Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors. Biology (Basel) (2012) 0.78

Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro. PLoS One (2013) 0.78

Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis. PLoS Comput Biol (2016) 0.77

Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction. Front Microbiol (2016) 0.77

Machine learning methods for prediction of CDK-inhibitors. PLoS One (2010) 0.76

Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial. PLoS One (2016) 0.75

Studies on quantitative phosphopeptide analysis by matrix-assisted laser desorption/ionization mass spectrometry without label, chromatography or calibration curves. Rapid Commun Mass Spectrom (2014) 0.75

Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice. PLoS One (2017) 0.75

A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell (1998) 10.14

GSK3 takes centre stage more than 20 years after its discovery. Biochem J (2001) 7.74

Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev (1997) 6.88

HIV-1 tat trans-activation requires the loop sequence within tar. Nature (1988) 6.87

P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol (2000) 5.64

Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proc Natl Acad Sci U S A (1989) 5.03

Human general transcription factor IIH phosphorylates the C-terminal domain of RNA polymerase II. Nature (1992) 4.63

GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol (2003) 4.60

The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev (1998) 4.38

RNA recognition by Tat-derived peptides: interaction in the major groove? Cell (1991) 3.83

Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J Virol (1995) 3.79

Tackling Tat. J Mol Biol (1999) 3.13

Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J (1998) 3.05

Recognition of RNA polymerase II carboxy-terminal domain by 3'-RNA-processing factors. Nature (2004) 2.86

Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol Cell Biol (2000) 2.58

TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc Natl Acad Sci U S A (1997) 2.52

Requirement for TFIIH kinase activity in transcription by RNA polymerase II. Nature (1995) 2.43

Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J Biol Chem (2004) 2.29

Tyrosine phosphorylation of mammalian RNA polymerase II carboxyl-terminal domain. Proc Natl Acad Sci U S A (1993) 2.17

Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci U S A (1994) 2.14

Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nat Med (2002) 2.13

Direct evidence that HIV-1 Tat stimulates RNA polymerase II carboxyl-terminal domain hyperphosphorylation during transcriptional elongation. J Mol Biol (1999) 2.01

Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem (2000) 1.93

CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA. Mol Cell Biol (2000) 1.89

Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci (2002) 1.82

RNA binding assays for Tat-derived peptides: implications for specificity. Biochemistry (1992) 1.65

HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. J Neurochem (1999) 1.53

Phosphorylation causes a conformational change in the carboxyl-terminal domain of the mouse RNA polymerase II largest subunit. J Biol Chem (1991) 1.50

Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J Med Chem (1999) 1.47

Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res (1999) 1.41

Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev (2002) 1.40

Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci (2003) 1.28

Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. J Virol (2002) 1.23

Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neurosci (2002) 1.20

Active beta-catenin signaling is an inhibitory pathway for human immunodeficiency virus replication in peripheral blood mononuclear cells. J Virol (2008) 1.18

Antiviral activity of CYC202 in HIV-1-infected cells. J Biol Chem (2004) 1.17

Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci (2005) 1.16

Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother (2002) 1.15

Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1. J Virol (2000) 1.12

RNA polymerase II C-terminal heptarepeat domain Ser-7 phosphorylation is established in a mediator-dependent fashion. J Biol Chem (2009) 1.12

Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs (2005) 1.11

Infection of human immunodeficiency virus and intracellular viral Tat protein exert a pro-survival effect in a human microglial cell line. J Mol Biol (2006) 1.07

The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication. J Virol (1994) 1.06

Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3beta to antagonize nuclear factor-kappaB survival pathway in neurons. Eur J Neurosci (2006) 1.05

Regulation of human immunodeficiency virus infection: implications for pathogenesis. Adv Virus Res (1994) 1.00

Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors. J Virol (2004) 0.98

Missing links in GSK3 regulation. Dev Biol (2001) 0.96

Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2005) 0.94

Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Curr Pharm Des (2006) 0.92

Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochim Biophys Acta (2004) 0.89

Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics. Curr HIV Res (2003) 0.88

Drug 9AA reactivates p21/Waf1 and Inhibits HIV-1 progeny formation. Virol J (2008) 0.87

R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury. Kidney Int (2005) 0.85

A model of the G1 phase of the cell cycle incorporating cyclin E/cdk2 complex and retinoblastoma protein. Oncogene (1995) 0.85

Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs. Curr Drug Targets Infect Disord (2005) 0.83

9-Aminoacridine inhibition of HIV-1 Tat dependent transcription. Virol J (2009) 0.80

Cdk inhibitory nucleoside analogs prevent transcription from viral genomes. Nucleosides Nucleotides Nucleic Acids (2005) 0.78

Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors. Virology (2011) 0.88